September 6, 2023

Modulation of TDP-43 condensates rescues ALS/FTD disease phenotypes in multi-stressor paradigms presented at ICGEB conference on TDP-43 function and dysfunction in disease

Media Contact

Jeanette Bressi
VP, Head of Communications & PR
Dewpoint Therapeutics
+1 609-439-3997 |

Investor Contact

Scott Peterson, Ph.D.
SVP, Corporate Development and Investor Relations
Dewpoint Therapeutics
Dewpoint Therapeutics
451 D Street, Suite 104
Boston, MA 02210
© 2019-2023 - Dewpoint Therapeutics

Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science